World Malaria Day: Malact Continues the Fight Against Malaria

Related Articles

Chewing Guava Leaves: A Treasure Trove of Health Benefits

2 weeks ago

What happens if you eat too much onion?

3 weeks ago

Are there any health benefits of eating broccoli?

4 weeks ago

Bed-ridden for weeks, fever rising and dropping at will, depression and fear setting in, the cold call of death looming over so many victims of Anopheles, the deadly malaria-carrying mosquito. This was something the Malact manufacturers couldn’t ignore any longer.

 

While we join the rest of the world in commemorating World Malaria Day, which is observed on April 25th each year, we must do everything we can to protect ourselves from the deadly disease.

In 2019, there were an estimated 229 million cases of malaria worldwide. According to the World Malaria Report, which was released on November 20th, 2020, the estimated number of malaria deaths was 409, 000.

Malact, an antimalarial drug developed by May and Baker Nigeria PLC, has the potential to revolutionize the way malaria is treated around the world. The medication is a Dihydroarteminsin-piperaquine combination formulation that provides immediate malaria relief and protection against relapse for up to 6 weeks.

 

Even though the World Health Organization (WHO) has since approved artemisinin-based combination therapies (ACTs) as the first-line drug for the treatment of uncomplicated malaria, most ACTs continue to have drawbacks, including treatment resistance.

 

As a result, Malact selected the dihydroartemisinin-piperaquine combination. Multiple trials have shown that the newer artemisinin-based combination therapy improves effectiveness and is considered the most effective medication currently available for the treatment of uncomplicated malaria.

 

Malaria has finally met its match. Malact will continue to fight against the disease. It will continue to protect its people from malaria relapse for up to six weeks and will work to make the country healthier and malaria-free.

 

• Malact emerged from a trusted source- May and Baker Plc.
• It contains Dihydroartemisinin 40mg and Piperaquine Phosphate 320mg
• It guarantees quick action
• Less treatment failure
• No relapse and recurrence of malaria for up to 6 weeks
• The single daily dose regimen
• Cost-effective

 

So, play your part in keeping an environment that isn’t mosquito friendly and we’ll play ours in protecting you against the disease.